Inavosilib in HR+/HER2- locally advanced or metastatic breast cancer
INAVO120 trial primary analysis shows benefits with inavosilib added to palbociclib and fulvestrant in PIK3CA-mutant locally advanced or metastatic breast cancer
INAVO120 trial primary analysis shows benefits with inavosilib added to palbociclib and fulvestrant in PIK3CA-mutant locally advanced or metastatic breast cancer